Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-10T09:24:07.530Z Has data issue: false hasContentIssue false

P.048 Characterization of somatic mutations in mTOR pathway genes in focal cortical dysplasias

Published online by Cambridge University Press:  05 June 2019

E Krochmalnek
Affiliation:
(Montreal)
A Accogli
Affiliation:
(Montreal)
J St-Onge
Affiliation:
(Montreal)
N Addour
Affiliation:
(Montreal)
R Dudley
Affiliation:
(Montreal)
K Myers
Affiliation:
(Montreal)
F Dubeau
Affiliation:
(Montreal)
J Karamchandani
Affiliation:
(Montreal)
J Farmer
Affiliation:
(Montreal)
J Atkinson
Affiliation:
(Montreal)
J Hall
Affiliation:
(Montreal)
C Poulin
Affiliation:
(Montreal)
B Rosenblatt
Affiliation:
(Montreal)
J Lafond Lapalme
Affiliation:
(Montreal)
S Albrecht
Affiliation:
(Montreal)
J Rivière
Affiliation:
(Montreal)
M Srour
Affiliation:
(Montreal)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Focal cortical dysplasias (FCDs) are congenital structural abnormalities of the brain, and represent the most common cause of medication-resistant focal epilepsy in children and adults. Recent studies have shown that somatic mutations (i.e. mutations arising in the embryo) in mTOR pathway genes underlie some FCD cases. Specific therapies targeting the mTOR pathway are available. However, testing for somatic mTOR pathway mutations in FCD tissue is not performed on a clinical basis, and the contribution of such mutations to the pathogenesis of FCD remains unknown. Aim: To investigate the feasibility of screening for somatic mutations in resected FCD tissue and determine the proportion and spatial distribution of FCDs which are due to low-level somatic mTOR pathway mutations. Methods: We performed ultra-deep sequencing of 13 mTOR pathway genes using a custom HaloPlexHS target enrichment kit (Agilent Technologies) in 16 resected histologically-confirmed FCD specimens. Results: We identified causal variants in 62.5% (10/16) of patients at an alternate allele frequency of 0.75–33.7%. The spatial mutation frequency correlated with the FCD lesion’s size and severity. Conclusions: Screening FCD tissue using a custom panel results in a high yield, and should be considered clinically given the important potential implications regarding surgical resection, medical management and genetic counselling.

Type
Poster Presentations
Copyright
© The Canadian Journal of Neurological Sciences Inc. 2019